在具有或没有EGFR突变的耐吉提尼布NSCLC中,GSK3β的双相功能
Junzhe Li1, Xiayu Wu2, Xiang-Bo Ji3
1Department of Thoracic Surgery, Affiliated Cancer Hospital of Hainan Medical University, Haikou, Hainan 570312, P.R. China.
Experimental and therapeutic medicine
|September 25, 2023
概括
在非小细胞肺癌 (NSCLC) 中获得的对gefitinib的耐药性涉及糖原合成酶激酶3β (GSK3β) 的变化. 这项研究研究了GSK3β.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学 是一个学科.
背景情况:
- 像gefitinib这样的表皮生长因子受体-氨酸激酶抑制剂 (EGFR-TKI) 对于治疗EGFR突变非小细胞肺癌 (NSCLC) 至关重要.
- 对EGFR-TKIs的获得性耐药性是一个重大的临床挑战,其潜在机制,特别是EGFR野生型NSCLC,尚未完全理解.
- 了解耐药机制对于开发有效的治疗策略对抗NSCLC至关重要.
研究的目的:
- 调查糖原合成酶激酶3β (GSK3β) 在非小细胞肺癌 (NSCLC) 中获得的格菲提尼布耐药性的作用.
- 为了比较gefitinib敏感和gefitinib抗性NSCLC细胞系之间的基因表达特征.
- 探索GSK3β和AKT通路调节对抗盖菲提尼布NSCLC细胞的功能影响.
主要方法:
- 产生抗盖菲提尼布的PC-9 (PC-9G) 细胞系.
- 全基因组转录组分析以确定差异表达的基因.
- 功能性检测包括细胞增殖,殖民地形成,入侵,迁移和流动细胞计.
- 通过过度表达和抑制/激活操纵GSK3β和AKT通路活性.
主要成果:
- 耐盖菲提尼布的PC-9G细胞对盖菲提尼布的敏感性降低,没有可检测的EGFR突变.
- 与敏感的PC-9细胞相比,在抗gefitinib的PC-9G细胞中,糖原合成酶激酶3β (GSK3β) 的下调显著.
- 过度表达GSK3β促进了缺乏EGFR突变的耐吉提尼布细胞的增殖,迁移和入侵,而AKT通路激活具有前瘤作用,表明复杂的相互作用.
结论:
- 糖原合成酶激酶3β (GSK3β) 在耐基菲替尼的非小细胞肺癌 (NSCLC) 中发挥着独特的作用,可能在EGFR突变的环境中起到瘤抑制作用,并在EGFR野生型耐药细胞中起到促进作用.
- GSK3β与AKT通路之间的相互作用是复杂的,并且在耐吉提尼布的NSCLC中取决于环境.
- 作为克服NSCLC中gefitinib耐药性的潜在治疗点,GSK3β需要进一步研究.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.9K
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
10.2K
相关概念视频
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
